nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—CYP3A7—Ifosfamide—testicular cancer	0.0735	0.106	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.0735	0.106	CbGbCtD
Fluvoxamine—CYP2B6—Ifosfamide—testicular cancer	0.07	0.101	CbGbCtD
Fluvoxamine—CYP3A5—Ifosfamide—testicular cancer	0.0551	0.0794	CbGbCtD
Fluvoxamine—CYP2C19—Ifosfamide—testicular cancer	0.0445	0.064	CbGbCtD
Fluvoxamine—CYP2C9—Ifosfamide—testicular cancer	0.037	0.0532	CbGbCtD
Fluvoxamine—CYP2B6—Cisplatin—testicular cancer	0.0341	0.049	CbGbCtD
Fluvoxamine—CYP2E1—Etoposide—testicular cancer	0.0339	0.0488	CbGbCtD
Fluvoxamine—ABCB1—Dactinomycin—testicular cancer	0.0304	0.0438	CbGbCtD
Fluvoxamine—CYP3A5—Etoposide—testicular cancer	0.0264	0.0379	CbGbCtD
Fluvoxamine—CYP2B6—Doxorubicin—testicular cancer	0.0228	0.0329	CbGbCtD
Fluvoxamine—CYP3A4—Ifosfamide—testicular cancer	0.0215	0.031	CbGbCtD
Fluvoxamine—CYP1A2—Etoposide—testicular cancer	0.0196	0.0282	CbGbCtD
Fluvoxamine—ABCB1—Vinblastine—testicular cancer	0.019	0.0274	CbGbCtD
Fluvoxamine—CYP2C9—Cisplatin—testicular cancer	0.018	0.0259	CbGbCtD
Fluvoxamine—CYP2D6—Vinblastine—testicular cancer	0.0179	0.0258	CbGbCtD
Fluvoxamine—ABCB1—Cisplatin—testicular cancer	0.0175	0.0251	CbGbCtD
Fluvoxamine—ABCB1—Etoposide—testicular cancer	0.0172	0.0247	CbGbCtD
Fluvoxamine—ABCB1—Doxorubicin—testicular cancer	0.0117	0.0168	CbGbCtD
Fluvoxamine—CYP3A4—Vinblastine—testicular cancer	0.0114	0.0164	CbGbCtD
Fluvoxamine—ABCB1—Methotrexate—testicular cancer	0.0113	0.0163	CbGbCtD
Fluvoxamine—CYP2D6—Doxorubicin—testicular cancer	0.011	0.0159	CbGbCtD
Fluvoxamine—CYP3A4—Etoposide—testicular cancer	0.0103	0.0148	CbGbCtD
Fluvoxamine—CYP3A4—Doxorubicin—testicular cancer	0.00701	0.0101	CbGbCtD
Fluvoxamine—Urticaria—Etoposide—testicular cancer	0.00012	0.000393	CcSEcCtD
Fluvoxamine—Haemoglobin—Epirubicin—testicular cancer	0.00012	0.000392	CcSEcCtD
Fluvoxamine—Stomatitis—Doxorubicin—testicular cancer	0.00012	0.000392	CcSEcCtD
Fluvoxamine—Jaundice—Doxorubicin—testicular cancer	0.00012	0.000392	CcSEcCtD
Fluvoxamine—Rhinitis—Epirubicin—testicular cancer	0.000119	0.000391	CcSEcCtD
Fluvoxamine—Abdominal pain—Etoposide—testicular cancer	0.000119	0.000391	CcSEcCtD
Fluvoxamine—Body temperature increased—Etoposide—testicular cancer	0.000119	0.000391	CcSEcCtD
Fluvoxamine—Urinary tract infection—Doxorubicin—testicular cancer	0.000119	0.000391	CcSEcCtD
Fluvoxamine—Conjunctivitis—Doxorubicin—testicular cancer	0.000119	0.000391	CcSEcCtD
Fluvoxamine—Hepatitis—Epirubicin—testicular cancer	0.000119	0.00039	CcSEcCtD
Fluvoxamine—Haemorrhage—Epirubicin—testicular cancer	0.000119	0.00039	CcSEcCtD
Fluvoxamine—Eye disorder—Methotrexate—testicular cancer	0.000119	0.000389	CcSEcCtD
Fluvoxamine—Tinnitus—Methotrexate—testicular cancer	0.000119	0.000388	CcSEcCtD
Fluvoxamine—Hypoaesthesia—Epirubicin—testicular cancer	0.000118	0.000388	CcSEcCtD
Fluvoxamine—Asthenia—Cisplatin—testicular cancer	0.000118	0.000387	CcSEcCtD
Fluvoxamine—Pharyngitis—Epirubicin—testicular cancer	0.000118	0.000387	CcSEcCtD
Fluvoxamine—Cardiac disorder—Methotrexate—testicular cancer	0.000118	0.000387	CcSEcCtD
Fluvoxamine—Sweating—Doxorubicin—testicular cancer	0.000118	0.000385	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Epirubicin—testicular cancer	0.000118	0.000385	CcSEcCtD
Fluvoxamine—Oedema peripheral—Epirubicin—testicular cancer	0.000117	0.000384	CcSEcCtD
Fluvoxamine—Haematuria—Doxorubicin—testicular cancer	0.000117	0.000383	CcSEcCtD
Fluvoxamine—Urethral disorder—Epirubicin—testicular cancer	0.000117	0.000382	CcSEcCtD
Fluvoxamine—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000116	0.00038	CcSEcCtD
Fluvoxamine—Epistaxis—Doxorubicin—testicular cancer	0.000116	0.000379	CcSEcCtD
Fluvoxamine—Angiopathy—Methotrexate—testicular cancer	0.000115	0.000378	CcSEcCtD
Fluvoxamine—Sinusitis—Doxorubicin—testicular cancer	0.000115	0.000377	CcSEcCtD
Fluvoxamine—Visual impairment—Epirubicin—testicular cancer	0.000115	0.000376	CcSEcCtD
Fluvoxamine—Agranulocytosis—Doxorubicin—testicular cancer	0.000115	0.000375	CcSEcCtD
Fluvoxamine—Chills—Methotrexate—testicular cancer	0.000114	0.000374	CcSEcCtD
Fluvoxamine—Nausea—Ifosfamide—testicular cancer	0.000113	0.000372	CcSEcCtD
Fluvoxamine—Diarrhoea—Cisplatin—testicular cancer	0.000113	0.000369	CcSEcCtD
Fluvoxamine—Erythema multiforme—Epirubicin—testicular cancer	0.000113	0.000369	CcSEcCtD
Fluvoxamine—Alopecia—Methotrexate—testicular cancer	0.000112	0.000368	CcSEcCtD
Fluvoxamine—Bradycardia—Doxorubicin—testicular cancer	0.000112	0.000367	CcSEcCtD
Fluvoxamine—Mental disorder—Methotrexate—testicular cancer	0.000111	0.000365	CcSEcCtD
Fluvoxamine—Eye disorder—Epirubicin—testicular cancer	0.000111	0.000364	CcSEcCtD
Fluvoxamine—Hypersensitivity—Etoposide—testicular cancer	0.000111	0.000364	CcSEcCtD
Fluvoxamine—Tinnitus—Epirubicin—testicular cancer	0.000111	0.000364	CcSEcCtD
Fluvoxamine—Malnutrition—Methotrexate—testicular cancer	0.000111	0.000363	CcSEcCtD
Fluvoxamine—Haemoglobin—Doxorubicin—testicular cancer	0.000111	0.000363	CcSEcCtD
Fluvoxamine—Cardiac disorder—Epirubicin—testicular cancer	0.000111	0.000362	CcSEcCtD
Fluvoxamine—Rhinitis—Doxorubicin—testicular cancer	0.00011	0.000362	CcSEcCtD
Fluvoxamine—Haemorrhage—Doxorubicin—testicular cancer	0.00011	0.000361	CcSEcCtD
Fluvoxamine—Hepatitis—Doxorubicin—testicular cancer	0.00011	0.000361	CcSEcCtD
Fluvoxamine—Hypoaesthesia—Doxorubicin—testicular cancer	0.00011	0.000359	CcSEcCtD
Fluvoxamine—Pharyngitis—Doxorubicin—testicular cancer	0.000109	0.000358	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Doxorubicin—testicular cancer	0.000109	0.000356	CcSEcCtD
Fluvoxamine—Oedema peripheral—Doxorubicin—testicular cancer	0.000109	0.000355	CcSEcCtD
Fluvoxamine—Dysgeusia—Methotrexate—testicular cancer	0.000108	0.000355	CcSEcCtD
Fluvoxamine—Asthenia—Etoposide—testicular cancer	0.000108	0.000355	CcSEcCtD
Fluvoxamine—Angiopathy—Epirubicin—testicular cancer	0.000108	0.000354	CcSEcCtD
Fluvoxamine—Urethral disorder—Doxorubicin—testicular cancer	0.000108	0.000354	CcSEcCtD
Fluvoxamine—Back pain—Methotrexate—testicular cancer	0.000107	0.000351	CcSEcCtD
Fluvoxamine—Chills—Epirubicin—testicular cancer	0.000107	0.00035	CcSEcCtD
Fluvoxamine—Pruritus—Etoposide—testicular cancer	0.000107	0.00035	CcSEcCtD
Fluvoxamine—Arrhythmia—Epirubicin—testicular cancer	0.000106	0.000348	CcSEcCtD
Fluvoxamine—Visual impairment—Doxorubicin—testicular cancer	0.000106	0.000348	CcSEcCtD
Fluvoxamine—Alopecia—Epirubicin—testicular cancer	0.000105	0.000345	CcSEcCtD
Fluvoxamine—Vomiting—Cisplatin—testicular cancer	0.000105	0.000343	CcSEcCtD
Fluvoxamine—Vision blurred—Methotrexate—testicular cancer	0.000104	0.000342	CcSEcCtD
Fluvoxamine—Mental disorder—Epirubicin—testicular cancer	0.000104	0.000342	CcSEcCtD
Fluvoxamine—Erythema multiforme—Doxorubicin—testicular cancer	0.000104	0.000341	CcSEcCtD
Fluvoxamine—Rash—Cisplatin—testicular cancer	0.000104	0.00034	CcSEcCtD
Fluvoxamine—Dermatitis—Cisplatin—testicular cancer	0.000104	0.00034	CcSEcCtD
Fluvoxamine—Malnutrition—Epirubicin—testicular cancer	0.000104	0.000339	CcSEcCtD
Fluvoxamine—Diarrhoea—Etoposide—testicular cancer	0.000103	0.000338	CcSEcCtD
Fluvoxamine—Eye disorder—Doxorubicin—testicular cancer	0.000103	0.000337	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Methotrexate—testicular cancer	0.000103	0.000337	CcSEcCtD
Fluvoxamine—Tinnitus—Doxorubicin—testicular cancer	0.000103	0.000336	CcSEcCtD
Fluvoxamine—Anaemia—Methotrexate—testicular cancer	0.000102	0.000335	CcSEcCtD
Fluvoxamine—Cardiac disorder—Doxorubicin—testicular cancer	0.000102	0.000335	CcSEcCtD
Fluvoxamine—Flatulence—Epirubicin—testicular cancer	0.000102	0.000334	CcSEcCtD
Fluvoxamine—Tension—Epirubicin—testicular cancer	0.000102	0.000333	CcSEcCtD
Fluvoxamine—Dysgeusia—Epirubicin—testicular cancer	0.000102	0.000332	CcSEcCtD
Fluvoxamine—Nervousness—Epirubicin—testicular cancer	0.000101	0.00033	CcSEcCtD
Fluvoxamine—Back pain—Epirubicin—testicular cancer	0.0001	0.000328	CcSEcCtD
Fluvoxamine—Angiopathy—Doxorubicin—testicular cancer	0.0001	0.000327	CcSEcCtD
Fluvoxamine—Malaise—Methotrexate—testicular cancer	9.99e-05	0.000327	CcSEcCtD
Fluvoxamine—Dizziness—Etoposide—testicular cancer	9.98e-05	0.000327	CcSEcCtD
Fluvoxamine—Muscle spasms—Epirubicin—testicular cancer	9.97e-05	0.000326	CcSEcCtD
Fluvoxamine—Vertigo—Methotrexate—testicular cancer	9.95e-05	0.000326	CcSEcCtD
Fluvoxamine—Leukopenia—Methotrexate—testicular cancer	9.91e-05	0.000325	CcSEcCtD
Fluvoxamine—Chills—Doxorubicin—testicular cancer	9.89e-05	0.000324	CcSEcCtD
Fluvoxamine—Arrhythmia—Doxorubicin—testicular cancer	9.84e-05	0.000322	CcSEcCtD
Fluvoxamine—Nausea—Cisplatin—testicular cancer	9.78e-05	0.00032	CcSEcCtD
Fluvoxamine—Vision blurred—Epirubicin—testicular cancer	9.77e-05	0.00032	CcSEcCtD
Fluvoxamine—Alopecia—Doxorubicin—testicular cancer	9.74e-05	0.000319	CcSEcCtD
Fluvoxamine—Cough—Methotrexate—testicular cancer	9.66e-05	0.000317	CcSEcCtD
Fluvoxamine—Mental disorder—Doxorubicin—testicular cancer	9.65e-05	0.000316	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Epirubicin—testicular cancer	9.62e-05	0.000315	CcSEcCtD
Fluvoxamine—Convulsion—Methotrexate—testicular cancer	9.6e-05	0.000314	CcSEcCtD
Fluvoxamine—Vomiting—Etoposide—testicular cancer	9.59e-05	0.000314	CcSEcCtD
Fluvoxamine—Malnutrition—Doxorubicin—testicular cancer	9.59e-05	0.000314	CcSEcCtD
Fluvoxamine—Anaemia—Epirubicin—testicular cancer	9.58e-05	0.000314	CcSEcCtD
Fluvoxamine—Agitation—Epirubicin—testicular cancer	9.53e-05	0.000312	CcSEcCtD
Fluvoxamine—Rash—Etoposide—testicular cancer	9.52e-05	0.000312	CcSEcCtD
Fluvoxamine—Dermatitis—Etoposide—testicular cancer	9.51e-05	0.000311	CcSEcCtD
Fluvoxamine—Headache—Etoposide—testicular cancer	9.45e-05	0.00031	CcSEcCtD
Fluvoxamine—Flatulence—Doxorubicin—testicular cancer	9.45e-05	0.000309	CcSEcCtD
Fluvoxamine—Myalgia—Methotrexate—testicular cancer	9.43e-05	0.000309	CcSEcCtD
Fluvoxamine—Chest pain—Methotrexate—testicular cancer	9.43e-05	0.000309	CcSEcCtD
Fluvoxamine—Arthralgia—Methotrexate—testicular cancer	9.43e-05	0.000309	CcSEcCtD
Fluvoxamine—Tension—Doxorubicin—testicular cancer	9.41e-05	0.000308	CcSEcCtD
Fluvoxamine—Dysgeusia—Doxorubicin—testicular cancer	9.39e-05	0.000308	CcSEcCtD
Fluvoxamine—Malaise—Epirubicin—testicular cancer	9.35e-05	0.000306	CcSEcCtD
Fluvoxamine—Discomfort—Methotrexate—testicular cancer	9.32e-05	0.000305	CcSEcCtD
Fluvoxamine—Nervousness—Doxorubicin—testicular cancer	9.31e-05	0.000305	CcSEcCtD
Fluvoxamine—Vertigo—Epirubicin—testicular cancer	9.31e-05	0.000305	CcSEcCtD
Fluvoxamine—Syncope—Epirubicin—testicular cancer	9.3e-05	0.000304	CcSEcCtD
Fluvoxamine—Leukopenia—Epirubicin—testicular cancer	9.28e-05	0.000304	CcSEcCtD
Fluvoxamine—Back pain—Doxorubicin—testicular cancer	9.28e-05	0.000304	CcSEcCtD
Fluvoxamine—Muscle spasms—Doxorubicin—testicular cancer	9.22e-05	0.000302	CcSEcCtD
Fluvoxamine—Palpitations—Epirubicin—testicular cancer	9.16e-05	0.0003	CcSEcCtD
Fluvoxamine—Confusional state—Methotrexate—testicular cancer	9.11e-05	0.000298	CcSEcCtD
Fluvoxamine—Loss of consciousness—Epirubicin—testicular cancer	9.11e-05	0.000298	CcSEcCtD
Fluvoxamine—Cough—Epirubicin—testicular cancer	9.04e-05	0.000296	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Methotrexate—testicular cancer	9.04e-05	0.000296	CcSEcCtD
Fluvoxamine—Vision blurred—Doxorubicin—testicular cancer	9.04e-05	0.000296	CcSEcCtD
Fluvoxamine—Convulsion—Epirubicin—testicular cancer	8.98e-05	0.000294	CcSEcCtD
Fluvoxamine—Infection—Methotrexate—testicular cancer	8.98e-05	0.000294	CcSEcCtD
Fluvoxamine—Nausea—Etoposide—testicular cancer	8.96e-05	0.000294	CcSEcCtD
Fluvoxamine—Hypertension—Epirubicin—testicular cancer	8.95e-05	0.000293	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Doxorubicin—testicular cancer	8.9e-05	0.000291	CcSEcCtD
Fluvoxamine—Nervous system disorder—Methotrexate—testicular cancer	8.86e-05	0.00029	CcSEcCtD
Fluvoxamine—Anaemia—Doxorubicin—testicular cancer	8.86e-05	0.00029	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Methotrexate—testicular cancer	8.85e-05	0.00029	CcSEcCtD
Fluvoxamine—Myalgia—Epirubicin—testicular cancer	8.82e-05	0.000289	CcSEcCtD
Fluvoxamine—Chest pain—Epirubicin—testicular cancer	8.82e-05	0.000289	CcSEcCtD
Fluvoxamine—Arthralgia—Epirubicin—testicular cancer	8.82e-05	0.000289	CcSEcCtD
Fluvoxamine—Agitation—Doxorubicin—testicular cancer	8.81e-05	0.000289	CcSEcCtD
Fluvoxamine—Anxiety—Epirubicin—testicular cancer	8.79e-05	0.000288	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Methotrexate—testicular cancer	8.74e-05	0.000286	CcSEcCtD
Fluvoxamine—Discomfort—Epirubicin—testicular cancer	8.72e-05	0.000286	CcSEcCtD
Fluvoxamine—Malaise—Doxorubicin—testicular cancer	8.65e-05	0.000283	CcSEcCtD
Fluvoxamine—Dry mouth—Epirubicin—testicular cancer	8.63e-05	0.000283	CcSEcCtD
Fluvoxamine—Vertigo—Doxorubicin—testicular cancer	8.62e-05	0.000282	CcSEcCtD
Fluvoxamine—Anorexia—Methotrexate—testicular cancer	8.62e-05	0.000282	CcSEcCtD
Fluvoxamine—Syncope—Doxorubicin—testicular cancer	8.6e-05	0.000282	CcSEcCtD
Fluvoxamine—Leukopenia—Doxorubicin—testicular cancer	8.58e-05	0.000281	CcSEcCtD
Fluvoxamine—Confusional state—Epirubicin—testicular cancer	8.53e-05	0.000279	CcSEcCtD
Fluvoxamine—Palpitations—Doxorubicin—testicular cancer	8.48e-05	0.000278	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Epirubicin—testicular cancer	8.46e-05	0.000277	CcSEcCtD
Fluvoxamine—Oedema—Epirubicin—testicular cancer	8.46e-05	0.000277	CcSEcCtD
Fluvoxamine—Hypotension—Methotrexate—testicular cancer	8.45e-05	0.000277	CcSEcCtD
Fluvoxamine—Loss of consciousness—Doxorubicin—testicular cancer	8.43e-05	0.000276	CcSEcCtD
Fluvoxamine—Infection—Epirubicin—testicular cancer	8.4e-05	0.000275	CcSEcCtD
Fluvoxamine—Cough—Doxorubicin—testicular cancer	8.37e-05	0.000274	CcSEcCtD
Fluvoxamine—Shock—Epirubicin—testicular cancer	8.32e-05	0.000273	CcSEcCtD
Fluvoxamine—Convulsion—Doxorubicin—testicular cancer	8.31e-05	0.000272	CcSEcCtD
Fluvoxamine—Nervous system disorder—Epirubicin—testicular cancer	8.3e-05	0.000272	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Epirubicin—testicular cancer	8.28e-05	0.000271	CcSEcCtD
Fluvoxamine—Hypertension—Doxorubicin—testicular cancer	8.28e-05	0.000271	CcSEcCtD
Fluvoxamine—Tachycardia—Epirubicin—testicular cancer	8.26e-05	0.00027	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Methotrexate—testicular cancer	8.24e-05	0.00027	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Epirubicin—testicular cancer	8.18e-05	0.000268	CcSEcCtD
Fluvoxamine—Insomnia—Methotrexate—testicular cancer	8.18e-05	0.000268	CcSEcCtD
Fluvoxamine—Chest pain—Doxorubicin—testicular cancer	8.16e-05	0.000267	CcSEcCtD
Fluvoxamine—Arthralgia—Doxorubicin—testicular cancer	8.16e-05	0.000267	CcSEcCtD
Fluvoxamine—Myalgia—Doxorubicin—testicular cancer	8.16e-05	0.000267	CcSEcCtD
Fluvoxamine—Anxiety—Doxorubicin—testicular cancer	8.14e-05	0.000266	CcSEcCtD
Fluvoxamine—Paraesthesia—Methotrexate—testicular cancer	8.12e-05	0.000266	CcSEcCtD
Fluvoxamine—Discomfort—Doxorubicin—testicular cancer	8.07e-05	0.000264	CcSEcCtD
Fluvoxamine—Anorexia—Epirubicin—testicular cancer	8.06e-05	0.000264	CcSEcCtD
Fluvoxamine—Dyspnoea—Methotrexate—testicular cancer	8.06e-05	0.000264	CcSEcCtD
Fluvoxamine—Somnolence—Methotrexate—testicular cancer	8.04e-05	0.000263	CcSEcCtD
Fluvoxamine—Dry mouth—Doxorubicin—testicular cancer	7.99e-05	0.000262	CcSEcCtD
Fluvoxamine—Dyspepsia—Methotrexate—testicular cancer	7.96e-05	0.000261	CcSEcCtD
Fluvoxamine—Hypotension—Epirubicin—testicular cancer	7.9e-05	0.000259	CcSEcCtD
Fluvoxamine—Confusional state—Doxorubicin—testicular cancer	7.89e-05	0.000258	CcSEcCtD
Fluvoxamine—Decreased appetite—Methotrexate—testicular cancer	7.86e-05	0.000257	CcSEcCtD
Fluvoxamine—Oedema—Doxorubicin—testicular cancer	7.83e-05	0.000256	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Doxorubicin—testicular cancer	7.83e-05	0.000256	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Methotrexate—testicular cancer	7.8e-05	0.000256	CcSEcCtD
Fluvoxamine—Fatigue—Methotrexate—testicular cancer	7.79e-05	0.000255	CcSEcCtD
Fluvoxamine—Infection—Doxorubicin—testicular cancer	7.78e-05	0.000255	CcSEcCtD
Fluvoxamine—Pain—Methotrexate—testicular cancer	7.73e-05	0.000253	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Epirubicin—testicular cancer	7.71e-05	0.000252	CcSEcCtD
Fluvoxamine—Shock—Doxorubicin—testicular cancer	7.7e-05	0.000252	CcSEcCtD
Fluvoxamine—Nervous system disorder—Doxorubicin—testicular cancer	7.68e-05	0.000251	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Doxorubicin—testicular cancer	7.66e-05	0.000251	CcSEcCtD
Fluvoxamine—Insomnia—Epirubicin—testicular cancer	7.65e-05	0.000251	CcSEcCtD
Fluvoxamine—Tachycardia—Doxorubicin—testicular cancer	7.64e-05	0.00025	CcSEcCtD
Fluvoxamine—Paraesthesia—Epirubicin—testicular cancer	7.6e-05	0.000249	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Doxorubicin—testicular cancer	7.57e-05	0.000248	CcSEcCtD
Fluvoxamine—Dyspnoea—Epirubicin—testicular cancer	7.54e-05	0.000247	CcSEcCtD
Fluvoxamine—Somnolence—Epirubicin—testicular cancer	7.52e-05	0.000246	CcSEcCtD
Fluvoxamine—Anorexia—Doxorubicin—testicular cancer	7.46e-05	0.000244	CcSEcCtD
Fluvoxamine—Feeling abnormal—Methotrexate—testicular cancer	7.45e-05	0.000244	CcSEcCtD
Fluvoxamine—Dyspepsia—Epirubicin—testicular cancer	7.45e-05	0.000244	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Methotrexate—testicular cancer	7.39e-05	0.000242	CcSEcCtD
Fluvoxamine—Decreased appetite—Epirubicin—testicular cancer	7.35e-05	0.000241	CcSEcCtD
Fluvoxamine—Hypotension—Doxorubicin—testicular cancer	7.31e-05	0.00024	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Epirubicin—testicular cancer	7.3e-05	0.000239	CcSEcCtD
Fluvoxamine—Fatigue—Epirubicin—testicular cancer	7.29e-05	0.000239	CcSEcCtD
Fluvoxamine—Pain—Epirubicin—testicular cancer	7.23e-05	0.000237	CcSEcCtD
Fluvoxamine—Constipation—Epirubicin—testicular cancer	7.23e-05	0.000237	CcSEcCtD
Fluvoxamine—Urticaria—Methotrexate—testicular cancer	7.18e-05	0.000235	CcSEcCtD
Fluvoxamine—Abdominal pain—Methotrexate—testicular cancer	7.15e-05	0.000234	CcSEcCtD
Fluvoxamine—Body temperature increased—Methotrexate—testicular cancer	7.15e-05	0.000234	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	7.13e-05	0.000234	CcSEcCtD
Fluvoxamine—Insomnia—Doxorubicin—testicular cancer	7.08e-05	0.000232	CcSEcCtD
Fluvoxamine—Paraesthesia—Doxorubicin—testicular cancer	7.03e-05	0.00023	CcSEcCtD
Fluvoxamine—Dyspnoea—Doxorubicin—testicular cancer	6.98e-05	0.000229	CcSEcCtD
Fluvoxamine—Feeling abnormal—Epirubicin—testicular cancer	6.97e-05	0.000228	CcSEcCtD
Fluvoxamine—Somnolence—Doxorubicin—testicular cancer	6.96e-05	0.000228	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Epirubicin—testicular cancer	6.92e-05	0.000227	CcSEcCtD
Fluvoxamine—Dyspepsia—Doxorubicin—testicular cancer	6.89e-05	0.000226	CcSEcCtD
Fluvoxamine—Decreased appetite—Doxorubicin—testicular cancer	6.8e-05	0.000223	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Doxorubicin—testicular cancer	6.76e-05	0.000221	CcSEcCtD
Fluvoxamine—Fatigue—Doxorubicin—testicular cancer	6.75e-05	0.000221	CcSEcCtD
Fluvoxamine—Urticaria—Epirubicin—testicular cancer	6.72e-05	0.00022	CcSEcCtD
Fluvoxamine—Constipation—Doxorubicin—testicular cancer	6.69e-05	0.000219	CcSEcCtD
Fluvoxamine—Pain—Doxorubicin—testicular cancer	6.69e-05	0.000219	CcSEcCtD
Fluvoxamine—Body temperature increased—Epirubicin—testicular cancer	6.69e-05	0.000219	CcSEcCtD
Fluvoxamine—Abdominal pain—Epirubicin—testicular cancer	6.69e-05	0.000219	CcSEcCtD
Fluvoxamine—Hypersensitivity—Methotrexate—testicular cancer	6.66e-05	0.000218	CcSEcCtD
Fluvoxamine—Asthenia—Methotrexate—testicular cancer	6.49e-05	0.000212	CcSEcCtD
Fluvoxamine—Feeling abnormal—Doxorubicin—testicular cancer	6.45e-05	0.000211	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Doxorubicin—testicular cancer	6.4e-05	0.00021	CcSEcCtD
Fluvoxamine—Pruritus—Methotrexate—testicular cancer	6.4e-05	0.000209	CcSEcCtD
Fluvoxamine—Hypersensitivity—Epirubicin—testicular cancer	6.23e-05	0.000204	CcSEcCtD
Fluvoxamine—Urticaria—Doxorubicin—testicular cancer	6.22e-05	0.000204	CcSEcCtD
Fluvoxamine—Abdominal pain—Doxorubicin—testicular cancer	6.19e-05	0.000203	CcSEcCtD
Fluvoxamine—Body temperature increased—Doxorubicin—testicular cancer	6.19e-05	0.000203	CcSEcCtD
Fluvoxamine—Diarrhoea—Methotrexate—testicular cancer	6.18e-05	0.000203	CcSEcCtD
Fluvoxamine—Asthenia—Epirubicin—testicular cancer	6.07e-05	0.000199	CcSEcCtD
Fluvoxamine—Pruritus—Epirubicin—testicular cancer	5.98e-05	0.000196	CcSEcCtD
Fluvoxamine—Dizziness—Methotrexate—testicular cancer	5.98e-05	0.000196	CcSEcCtD
Fluvoxamine—Diarrhoea—Epirubicin—testicular cancer	5.79e-05	0.00019	CcSEcCtD
Fluvoxamine—Hypersensitivity—Doxorubicin—testicular cancer	5.77e-05	0.000189	CcSEcCtD
Fluvoxamine—Vomiting—Methotrexate—testicular cancer	5.75e-05	0.000188	CcSEcCtD
Fluvoxamine—Rash—Methotrexate—testicular cancer	5.7e-05	0.000187	CcSEcCtD
Fluvoxamine—Dermatitis—Methotrexate—testicular cancer	5.69e-05	0.000186	CcSEcCtD
Fluvoxamine—Headache—Methotrexate—testicular cancer	5.66e-05	0.000185	CcSEcCtD
Fluvoxamine—Asthenia—Doxorubicin—testicular cancer	5.62e-05	0.000184	CcSEcCtD
Fluvoxamine—Dizziness—Epirubicin—testicular cancer	5.59e-05	0.000183	CcSEcCtD
Fluvoxamine—Pruritus—Doxorubicin—testicular cancer	5.54e-05	0.000181	CcSEcCtD
Fluvoxamine—Vomiting—Epirubicin—testicular cancer	5.38e-05	0.000176	CcSEcCtD
Fluvoxamine—Nausea—Methotrexate—testicular cancer	5.37e-05	0.000176	CcSEcCtD
Fluvoxamine—Diarrhoea—Doxorubicin—testicular cancer	5.36e-05	0.000175	CcSEcCtD
Fluvoxamine—Rash—Epirubicin—testicular cancer	5.33e-05	0.000175	CcSEcCtD
Fluvoxamine—Dermatitis—Epirubicin—testicular cancer	5.33e-05	0.000175	CcSEcCtD
Fluvoxamine—Headache—Epirubicin—testicular cancer	5.3e-05	0.000174	CcSEcCtD
Fluvoxamine—Dizziness—Doxorubicin—testicular cancer	5.18e-05	0.00017	CcSEcCtD
Fluvoxamine—Nausea—Epirubicin—testicular cancer	5.02e-05	0.000165	CcSEcCtD
Fluvoxamine—Vomiting—Doxorubicin—testicular cancer	4.98e-05	0.000163	CcSEcCtD
Fluvoxamine—Rash—Doxorubicin—testicular cancer	4.94e-05	0.000162	CcSEcCtD
Fluvoxamine—Dermatitis—Doxorubicin—testicular cancer	4.93e-05	0.000161	CcSEcCtD
Fluvoxamine—Headache—Doxorubicin—testicular cancer	4.9e-05	0.000161	CcSEcCtD
Fluvoxamine—Nausea—Doxorubicin—testicular cancer	4.65e-05	0.000152	CcSEcCtD
